Safety and efficacy data on the investigational subcutaneous formulation of ORENCIA in adults with moderate to severe rheumatoid arthritis to be presented at the American College of Rheumatology ...

If you have certain types of arthritis or if you’re having a certain transplant, your doctor might suggest Orencia (abatacept) as a treatment option for you. Orencia is a prescription medication ...

Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...

Please provide your email address to receive an email when new articles are posted on . Bristol-Myers Squibb Company announced the commercial launch of the Orencia ClickJect, a self-administered ...

Patients with RA who use abatacept mount little humoral or cell-mediated responses to the recombinant zoster vaccine, with more injection-site reactions but similar RA flare rates compared with ...

August 2, 2011 — The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of abatacept (Orencia, Bristol-Myers Squibb Co) for the treatment of adults with moderate-to-severe ...

Please provide your email address to receive an email when new articles are posted on . Bristol-Myers Squibb Company announced Orencia intravenous infusion and subcutaneous injection in combination ...

(NAPSI)ORENCIA (abatacept) is the first and only biologic for the treatment of adults with moderate to severe rheumatoid arthritis (RA) available in both self-injectable (under the skin) and ...

The approval of the prefilled syringe was based on dosing, efficacy, and safety data of SC abatacept in JIA among patients aged 2-17 years with inadequate response to at least one nonbiologic or ...

NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a ...